Do 5α-Reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention?
نویسندگان
چکیده
منابع مشابه
Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, taking into consideration various factors like efficacy, dosing regime, adverse effects, cost, patient...
متن کاملCurrent Status of 5α-Reductase Inhibitors in Prostate Disease Management
The key enzyme in the androgen synthesis and androgen receptor pathways is 5α-reductase (5-AR), which occurs as three isoenzymes. Types I and II 5-ARs the most important clinically, and two different 5-AR inhibitors (5-ARIs), finasteride and dutasteride, have been developed. Several urology associations have recommended and upgraded the use of 5-ARIs for an enlarged prostate with lower urinary ...
متن کاملCIA-4102-combination therapy with dutasteride
Correspondence: Thomas H Tarter Division of Urology, Southern Illinois University School of Medicine, PO Box 19665, Springfield, IL 62794-9665, US. Tel +1 217 545 7390 Fax +1 217 545 7305 email [email protected] Abstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial ...
متن کاملRe: 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men with Prostate Cancer.
IMPORTANCE 5α-Reductase inhibitors (5-ARIs) are widely used in the treatment of benign prostatic hyperplasia. However, randomized clinical trials have raised concerns that their use may be associated with an increased risk of high-grade prostate cancer tumors that would ultimately lead to worse prostate cancer outcomes. To date, few observational studies have addressed this important safety con...
متن کاملManagement of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey.
OBJECTIVE To analyse current practice in the management of acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH) in the UK, and to assess how much of this is evidence-based. METHODS In all, 410 consultant urologists practising in UK hospitals were sent a questionnaire about the management of AUR secondary to BPH. Data were collected on practice relating to initial mana...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Urological Science
سال: 2018
ISSN: 1879-5226
DOI: 10.4103/uros.uros_6_17